The messenger RNA vaccine does not meet the required criteria at this stage, said the German laboratory, which has signed a major ordering contract with the European Union.
German laboratory CureVac announced on Wednesday that its leading COVID-19 vaccine candidate had only shown 47% efficacy, according to the interim analysis of a large-scale clinical trial, and was not fulfilling at this stage. the required criteria.
The vaccine “Achieved a preliminary efficacy of 47% against COVID-19, regardless of its severity, not meeting the pre-specified statistical criteria of success”, said in a press release the laboratory which has signed a major order contract with the European Union for this messenger RNA vaccine.
To see also – Olivier Véran welcomes the launch of vaccination for 12-17 year olds